

図 1. 4 種類のヒト GPCR を標的とした CFP による発現量モニタリング




図 2. シグナル配列を付加した SSTR5 によるシグナル伝達効率の比較

塩基部 6 位に蛍光性残基を導入したプリンヌクレオシドを含むオリゴヌクレオチドの合成とその特性

研究分担者：上野 義仁 岐阜大学応用生物科学部・准教授

研究要旨

新しい核酸蛍光プローブの創製を目指し、デオキシアデノシンの塩基部 6 位にナフタレン及びピレンを導入した蛍光性人工核酸 A^N 、 A^P を合成し、 A^N 、 A^P を含むオリゴマーの熱的安定性、蛍光特性を検証した。その結果、 A^P を含むオリゴマーが二重鎖安定化能、蛍光特性の観点から核酸蛍光プローブとして有望であることが分かった。

A. 研究目的

上野はこれまで、核酸の糖部をベンゼン環に置換した人工核酸を合成し、その性質を検証している。その結果、この人工核酸がアナログ体同士で熱的・熱力学的に安定な二重鎖を形成すること、また、塩基をナフタレンやピレンで置換したビアリール型ユニットをオリゴヌクレオチド中に連続して導入すると、二重鎖が熱的・熱力学的に安定化されること、及び二重鎖を形成した際に蛍光強度が相乗的に増大することを見出している。これらの知見をもとに、本年度は、新しい核酸蛍光プローブの創製を目指し、デオキシアデノシンの塩基部 6 位にナフタレン及びピレンを導入した新たな蛍光性人工核酸 A^N 、 A^P の合成を行なった。この人工核酸は塩基と芳香環の間に回転軸を持ち、オリゴマー中ではその回転軸が回転することで効果的な相互作用をもたらし、安

定な二重鎖を形成するとともに、励起子相互作用に基づく強い蛍光を発すると考えた。

B. 研究方法

各溶媒中濃度 $30\mu\text{M}$ にて、化合物 A^N の吸光度測定および蛍光測定を行った。励起波長 316nm にて蛍光強度を測定した。各溶媒中濃度 $3\mu\text{M}$ にて、化合物 A^P の吸光度測定および蛍光測定を行った。励起波長 355nm にて蛍光強度を測定した。核酸自動合成機にて DNA を合成した。合成した DNA は MALDI-TOFMS での分子量測定にて目的の配列を得たことを確認した。 $10\text{mM Na Phosphate (pH = 7.0)}$ 、 100nM NaCl 中、 $3\mu\text{M}$ の濃度にて各二本鎖をアニーリングさせた後、50%解離温度である T_m 値を測定した。一本鎖濃度 $2, 4, 6, 10, 16, 26, 44, 70, 120, 200\mu\text{M}$ にて T_m 値を測定し、Van't Hoff プロットを行った。

C. 研究結果

アナログ A^N は溶媒の極性に依存した蛍光強度を持つこと、また、その蛍光量子収率は溶媒の極性に反比例することが明らかとなった。また、アナログ A^P も溶媒の極性に依存して極大蛍光波長が変化することが分かった。

dA を導入した配列と比較し、 A^N 、 A^P を導入した配列において T_m 値が上昇し、熱的安定性が向上した。また、dA の導入数が増加すると熱的安定性が減少するのに対し、 A^N 、 A^P の導入数が増加すると熱的安定性も相対的に増加した。これは導入したナフタレン、ピレン残基の π - π スタッキングに起因するものであると推定される。

オリゴマーの UV 吸収の強度は測定した温度に依存した。ネイティブには見られない吸収がアナログ A^N を導入したオリゴマーでは 300-380nm に、 A^P を導入したオリゴマーでは 340-440nm に観察された。

A^N を入れたオリゴマーにおいて ΔS° が増加し、自由エネルギー変化 ΔG° が減少することで二本鎖がより安定化された。導入した A^N は二本鎖形成を阻害せず、ナフタレン残基による疎水性およびスタッキング相互作用にて二本鎖を安定化していることが示唆された。

A^N 挿入オリゴマーにおいては、2 つ挿入した mon5 において、3 つ挿入した 7 よりも蛍光が大きくなった。この結果は A^N の高次構造形成によるものではないことが示唆された。 A^P 挿入オリゴマーにお

いては、2 つ挿入した鎖では、二本鎖を組ませる以前からエキシマーによる長波長シフトが見られた。

それぞれのアナログ導入 DNA での極大蛍光波長は A^N : 420-460nm A^P : 473-500nm であった。また、アナログを多数導入すると、蛍光波長が長波長シフトし、蛍光強度が増加した。さらに、センス鎖、アンチセンス鎖で同じ数のアナログを導入した配列に比べ、異なる数のアナログを導入した配列において蛍光強度が増大した。

D. 考察

今回設計・合成した蛍光性人工核酸はこれまでに報告されている他の蛍光核酸に比べ合成が簡便であり、かつ非常に強い蛍光強度を持つことから遺伝子解析技術の 1 つである DNA チップを初めとし、機能性核酸として医薬品への応用が期待されているアプタマーや siRNA など、幅広い応用が可能である。

E. 結論

新しい核酸蛍光プローブの創製を目指し、デオキシアデノシンの塩基部 6 位にナフタレン及びピレンを導入した蛍光性人工核酸 A^N 、 A^P を合成し、 A^N 、 A^P を含むオリゴマーの熱的安定性、蛍光特性を検証した。その結果、 A^P を含むオリゴマーが二重鎖安定化能、蛍光特性の観点から核酸蛍光プローブとして有望であることが明らかとなった。

F. 研究発表

学会発表

岩田 麻里、上野 義仁; 塩基部 6 位に蛍光性残基を導入したプリンヌクレオシドを含むオリゴヌクレオチドの合成とその特性; 第 21 回アンチセンスシンポジウム, 講演要旨集 p63, 2011.

論文

1. Shibata, A., Unoe, Y., Iwata, M., Wakita, H., Mastuda, A. and Kitade, Y.

Bioorganic & Medical Chemistry Letters
22 (2012) 2681-2683



2. Furukawa, K., Hattori, M., Ohki, T., Kitamura, Y and Ueno, Y.

Bioorganic & Medical Chemistry
20 (2012) 16-24

G. 知的財産の出願・登録状況



該当なし

A^N , A^P モノマー 蛍光測定




オリゴ合成(1)

MALDI-TOF / MS 結果




Name	sequence	calculated	observed
MOD1	5'-CGGCACGAGCGGC-3'	3985.59	3983.70
MOD2	3'-GCCGTGCTCGCCG-5'	3927.54	3925.88
MOD3	5'-CGGCANCGAGCGGC-3'	4409.95	4411.06
MOD3p	5'-CGGCAPCGAGCGGC-3'	4484.03	4484.42
MOD4	3'-GCCGTNGCTCGCCG-5'	4351.89	4353.55
MOD4p	3'-GCCGTPGCTCGCCG-5'	4425.97	4426.70
MOD5	5'-CGGCAN NCGAGCGGC-3'	4834.30	4839.67
MOD5p	5'-CGGCAP NCGAGCGGC-3'	4982.46	4983.44
MOD6	3'-GCCGTN NGCTCGCCG-5'	4776.25	4780.25
MOD6p	3'-GCCGTP NGCTCGCCG-5'	4924.41	4929.29
MOD7	5'-CGGCAN N NCGAGCGGC-3'	5258.65	5261.49
MOD8	5'-CGGCACGAGCGGC-3'	4298.80	4297.08
MOD9	3'-GCCGTAGCTCGCCG-5'	4240.75	4241.29
MOD10	5'-CGGCAACGAGCGGC-3'	4612.01	4612.46
MOD11	3'-GCCGTAAGCTCGCCG-5'	4553.96	4549.67
MOD12	5'-CGGCAAAACGAGCGGC-3'	4295.22	4296.76

DNA一本鎖蛍光測定



オリゴマー T_m 測定

Sequence	mon	X	Y	T_m (°C)
5'-CGGCA CGAGCGGC-3' 3'-GCCGT GCTCGCCG-5'	mon1			70.3
5'-CGGCA XCGAGCGGC-3' 3'-GCCGT GCTCGCCG-5'	mon8	A	/	62.5
	mon2	A ^N	/	64.7
	mon2p	A ^P	/	62.4
5'-CGGCA XCGAGCGGC-3' 3'-GCCGT YGCTCGCCG-5'	mon9	A	A	61.6
	mon3	A ^N	A ^N	64.6
	mon3p	A ^P	A ^P	63.2
5'-CGGCA XXCGAGCGGC-3' 3'-GCCGT Y GCTCGCCG-5'	mon10	A	A	58.0
	mon4	A ^N	A ^N	63.3
	mon4p	A ^P	A ^P	62.8
5'-CGGCA X CGAGCGGC-3' 3'-GCCGT YYGCTCGCCG-5'	mon11	A	A	55.6
	mon5	A ^N	A ^N	62.7
	mon5p	A ^P	A ^P	62.6
5'-CGGCA XXCGAGCGGC-3' 3'-GCCGT YYGCTCGCCG-5'	mon12	A	A	56.6
	mon6	A ^N	A ^N	63.7
	mon6p	A ^P	A ^P	64.5
5'-CGGCA XXXCGAGCGGC-3' 3'-GCCGT YY GCTCGCCG-5'	mon13	A	A	53.4
	mon7	A ^N	A ^N	63.5





T_m were measured in a buffer of 10mM NaPhosphate (pH 7.0) and 100mM NaCl with 3 μ M of each oligomer.

オリゴマー van't Hoff 測定

$$\Delta G^\circ = \Delta H^\circ - T \Delta S^\circ$$

$$1 / T_m = (R / \Delta H^\circ) / \ln(Ct/4) + (\Delta S^\circ / \Delta H^\circ)$$





	Sequence	ΔH° (kcal/mol)	ΔS° (cal/K·mol)	ΔG°_{298} (kcal/mol)
mon12	5'-CGGCAAACGAGCGGC-3' 3'-GCCGTAAGCTCGCCG-5'	-141.4	-404.0	-21.0
mon6	5'-CGGCANNCGAGCGGC-3' 3'-GCCGTNNGCTCGCCG-5'	-141.4	-395.1	-23.7

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ishizaka A, Mizutani T, Kobayashi K, Tando T, Sakurai K, <u>Fujiwara T</u> , Iba H	Double PHD finger proteins DPF3a and 3b are required as transcriptional coactivators in the SWI/SNF complex-dependent activation of the NF- κ B RelA/p50 heterodimer.	Journal of Biological Chemistry	287	11924-11933	2012
Mishima Y, Fukao A, Kishimoto T, Sakamoto H, <u>Fujiwara T</u> , Inoue K.	Translational inhibition by deadenylation-independent mechanisms is central to microRNA-mediated silencing in zebrafish	Proc. Natl. Acad. Sci. USA	109	1104-1109	2012
<u>Fujiwara T</u> , Fukao A, Sasano Y, Matsuzaki H, Kikkawa U, Imataka H, Inoue K, Endo S, Sonenberg N, Thoma C, Sakamoto H	Functional and direct interaction between the RNA binding protein HuD and active Akt1	Nucleic Acids Research	40	1944-11953	2012
Singh CR, Watanabe R, Zhou D, Jennings MD, Fukao A, Lee B, Ikeda Y, Chiorini JA, Campbell SG, Ashem MP, <u>Fujiwara T</u> , Wek RC, Pavitt GD, Asano K	Functional and direct interaction between the RNA binding protein HuD and active Akt1	Nucleic Acids Research	39	8314-8328	2011
Ishii J, Yoshimoto N, Tatematsu K, Kuroda S, Ogino C, Fukuda H, Kondo A.	Cell wall trapping of autocrine peptides for human G-protein-coupled receptors on the yeast cell surface.	J PLoS One.	7	e37136	2012
Ishii J, Moriguchi M, Hara KY, Shibasaki S, Fukuda H, Kondo A.	Improved identification of agonist-mediated G α i-specific human G-protein-coupled receptor signaling in yeast cells by flow cytometry	Anal Biochem	426	129-133	2012
Ryo S, Ishii J, Iguchi Y, Fukuda N, Kondo A.	Transplantation of the GAL regulon into G-protein signaling circuitry in yeast.	Anal Biochem	424	27-31	2012
Fukuda N, Ishii J, Kaishima M, Kondo A.	Amplification of agonist stimulation of human G-protein-coupled receptor signaling in yeast.	Anal Biochem	417	182-187	2011

Shibata, A., Unoe, Y., Iwata, M., Wakita, H., Mastuda, A. and Kitade, Y.	Double-stranded oligonucleotides containing 5-aminomethyl-2'-deoxyuridine from thermostable antiparallel triplexes with single-stranded DNA or RNA	Bioorganic & Medical Chemistry Letters	22	2681-2683	2012
Furukawa, K., Hattori, M., Ohki, T., Kitamura, Y and Ueno, Y	Nucleic acid probe containing fluorescent tricyclic base-linked acrylonucleoside for detection of single nucleotide polymorphism	Bioorganic & Medical Chemistry	20	16-24	2012



Amplification of agonist stimulation of human G-protein-coupled receptor signaling in yeast

Nobuo Fukuda^a, Jun Ishii^b, Misato Kaishima^a, Akihiko Kondo^{a,*}

^aDepartment of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Nada-ku, Kobe 657-8501, Japan

^bOrganization of Advanced Science and Technology, Kobe University, Nada-ku, Kobe 657-8501, Japan

ARTICLE INFO

Article history:

Received 11 March 2011

Received in revised form 27 May 2011

Accepted 6 June 2011

Available online 13 June 2011

Keywords:

Yeast

GPCR

G-protein signaling

Gβ subunit

Feedback signal activation

ABSTRACT

G-protein-coupled receptors (GPCRs) are considered as important targets for drug discovery. The yeast *Saccharomyces cerevisiae* is an attractive host for high-throughput screening of agonistic ligands for human GPCRs because it can simplify the complicated signaling pathways that are present in mammalian cell lines. Unfortunately, many human GPCRs induce only partial signal activation in yeast cells depending on their coupling efficiency with yeast G-proteins. This problem often results in unsatisfactory detection sensitivity, thereby resulting in a limitation to yeast-based detection systems. Here we introduce a new highly sensitive detection method that provides robust agonist detection of human GPCRs. Our strategy is designed to invoke feedback activation of signals within yeast G-protein signaling pathways. Briefly, agonist stimulation of human GPCRs triggers expression of an artificial signal activator that amplifies signaling. We chose human somatostatin receptor subtype 5 (hSSTR5) as a model of a human GPCR. Investigation of the response of hSSTR5-expressing yeast to various concentrations of somatostatin demonstrated that feedback activation of the signal can successfully improve the detection limit and the maximum level of signaling. This novel approach will enhance the usefulness of yeast-based screening of agonistic ligands for a variety of human GPCRs.

© 2011 Elsevier Inc. All rights reserved.

G-protein-coupled receptors (GPCRs)¹ constitute the largest family of transmembrane proteins and play an important part in signal transduction by converting extracellular stimuli into intracellular signals. Currently, more than 30% of marketed medicines act on GPCRs, which are still considered as attractive targets for new medicines [1]. To develop new medicines, it is necessary to evaluate a lot of candidates due to the low frequency of discovery of lead compounds. Therefore, high-throughput screening (HTS) of active compounds has become an integral technology in pharmaceutical laboratories [2].

The budding yeast *Saccharomyces cerevisiae* is an attractive host cell system for identification of agonistic ligands that can modulate the functions of human GPCRs because the mechanisms of G-protein signaling are highly conserved among a diverse range of eukaryotes from yeast to mammals. The yeast system, which is composed of an uncompetitive and monopolistic G-protein signaling pathway (the pheromone signaling pathway) [3], is more

simple than the complicated G-protein signaling that occurs in mammalian cell lines. It has also been reported that a variety of human GPCRs can successfully activate the yeast signaling pathway when expressed in yeast cells. These receptors respond to binding of their agonists and transmit signals via coupling with the endogenous yeast G-protein, which is a heterotrimer consisting of Gα, Gβ, and Gγ subunits [4]. Whereas a heterotrimeric Gαβγ complex is formed in the unstimulated state (without agonistic ligand), binding of agonist to the receptor induces dissociation of the heterotrimeric G-protein into monomeric Gα and a Gβγ complex, which is accompanied by the exchange of GDP for GTP on the Gα subunit (Fig. 1A). In yeast, the dissociated Gβγ complex activates intracellular effector proteins that stimulate the mitogen-activated protein kinase (MAPK) cascade, resulting in changes in cell behavior (Fig. 1A).

Because cellular responses to MAPK activation, including changes in gene transcription, can be used to detect GPCR agonist-induced signaling, several reporter gene assays have been adopted to assay the signaling stimulated by GPCR agonists in yeast systems (Fig. 1A). Although the *HIS3* and *lacZ* genes [5,6] are conventional reporter genes that are used for auxotrophic screening and colorimetric evaluation, respectively, it was recently reported that a *GFP* fluorescent reporter gene can be used for quantitative HTS using flow cytometry [7–9]. One problem with using

* Corresponding author. Fax: +81 78 803 6196.

E-mail address: akondo@kobe-u.ac.jp (A. Kondo).

¹ Abbreviations used: GPCR, G-protein-coupled receptor; HTS, high-throughput screening; MAPK, mitogen-activated protein kinase; hSSTR5, human somatostatin receptor subtype 5; PCR, polymerase chain reaction; EGFP, enhanced green fluorescent protein; SST, somatostatin.




Fig. 1. (A) Schematic outline of the strategy of feedback signal activation system commonly used to analyze agonist stimulation of GPCRs using the yeast pheromone signaling pathway. Agonistic ligand binding to the GPCR leads to activation of heterotrimeric G-proteins composed of Gpa1 ($G\alpha$), Ste4 ($G\beta$), and Ste18 ($G\gamma$). The activated G-proteins subsequently dissociate into $G\alpha$ and a $G\beta\gamma$ dimer. The $G\beta\gamma$ dimer induces activation of the MAPK cascade, resulting in expression of a GFP reporter gene. (B) Feedback signal activation approach for robust and highly sensitive detection of GPCR agonists. Ligand stimulation induces the expression of both GFP and STE4 ($G\beta$) genes. This $G\beta$ that is overexpressed in a signal-responsive manner competes with endogenous $G\beta$ present in the $G\alpha\beta\gamma$ heterotrimer for $G\alpha$ binding. Such competition releases a free $G\beta\gamma$ complex that can amplify the weak signal caused by partial coupling between the heterologous GPCR and endogenous yeast G-protein. The resulting intense green fluorescence improves the sensitivity of heterologous GPCR signal detection.

yeast systems for analysis of human GPCR signaling is that the level of the signals transmitted from human GPCRs is commonly lower than that from the endogenous yeast GPCR due to inefficient coupling between the yeast G-protein and the human GPCR [10]. Thus, high signal-to-noise ratio in reporter gene assays is a critical factor in order to achieve powerful and reliable screening of human GPCR agonists. Therefore, a highly sensitive system that can detect reporter genes in yeast even in response to weak signals would be beneficial for screening of human GPCR agonists.

Here we describe a novel strategy to improve the sensitivity of detection of agonist-dependent signaling of a human GPCR that is expressed on a yeast cell surface. Because this strategy involves signal-induced expression of a gene encoding an activator ($G\beta$ subunit) of the effector protein that is the output of yeast G-protein signaling, induction of this gene is expected to result in persistent activation of the MAPK cascade after signal initiation (Fig. 1B). Thus, agonist addition switches on “feedback signal activation” of yeast G-protein signaling. In the current study, we show the feasibility of this approach and its potency for the detection of human GPCR agonists.

Materials and methods

Strains, plasmids, and media

The genotypes of the *S. cerevisiae* strains and plasmids used in this study are outlined in Table 1. Yeast cells were grown in YPD medium containing 1% (w/v) yeast extract, 2% peptone, and 2% glucose, in SD medium containing 0.67% yeast nitrogen base without amino acids (Becton Dickinson, Franklin Lakes, NJ, USA) and 2% glucose, or in SDM71 medium (SD medium adjusted to pH 7.1 with 200 mM Mopso buffer) [11].

Construction of plasmids

To express the STE4 gene (encoding $G\beta$) under the control of the pheromone-responsive FIG1 promoter [11–15], the STE4 gene was inserted into a plasmid that integrated into the yeast chromosome at a position upstream of the HOP2 gene (P_{HOP2} :HOP2 promoter region). Plasmid construction was as follows. The STE4 gene was amplified from BY4741 [16] genomic DNA using the primers 5'-aaaaGTCGACatggactacaaggatgacgatgacaaggcagcacatcagatggactgataacctg-3' and 5'-aaaaGGATCCtattgataacctggagacc-3' (restriction enzyme sites are in uppercase letters) and was inserted into the Sall–BamHI sites of pLMFIG-STE18-H [17], yielding the plasmid pLMFIG-STE4-H.

The plasmid used for expression of the human somatostatin receptor subtype 5 (hSSTR5) was constructed as follows. A DNA fragment encoding the hSSTR5 gene was amplified from pGK-SSTR5-HA [11] using the primers 5'-ccccGTCGACatggagccctgtcc cagc-3' and 5'-ccccGAATTCcagactgtgctgctgca-3' (restriction enzyme sites are in uppercase letters) and was inserted into the Sall–EcoRI sites between the PGK1 promoter (P_{PGK1}) and the PGK1 terminator (T_{PGK1}) on pGK423 [18], yielding the plasmid pHM-SSTR5 (Table 1).

Construction of yeast strains

Each DNA fragment was introduced into yeast cells using the lithium acetate method [19]. The DNA fragments containing LEU2- P_{FIG1} -STE4- T_{PGK1} - P_{HOP2} were amplified from pLMFIG-STE4-H using the primers 5'-atacaattaattgacatcagcagacagcaaatgacttgata-taccagctgactacgtcgtaaggccg-3' (corresponding to 50 nt of the region directly upstream of P_{HOP2}) and 5'-atcttcaaatagacgctgg-3' and were used to transform MC-F1 [17]. The transformants were

Table 1
List of yeast strains and plasmids used in this study.

Strain or plasmid	Description	Reference source
<i>Yeast strains</i>		
BY4741	MATA his3 Δ 1 ura3 Δ 0 leu2 Δ 0 met15 Δ 0	[16]
MC-F1	BY4741 fig1::FIG1-EGFP	[17]
MC-F1B	MC-F1 P_{HOP2} ::LEU2- P_{FIG1} -STE4	This study
IMFD-70	BY4741 sst2 Δ ::AUR1-C ste2 Δ ::LEU2 fig1 Δ ::EGFP his3 Δ :: P_{FIG1} -EGFP far1 Δ	[11]
IMFD-70B	IMFD-70 P_{HOP2} ::URA3- P_{FIG1} -STE4	This study
<i>Plasmids</i>		
pGK411	Yeast expression vector containing PGK1 promoter, CEN/ARS origin, and MET15 marker	[21]
pGK411-STE2	STE2 in pGK411	[21]
pGK423	Yeast expression vector containing PGK1 promoter, 2 μ origin, and HIS3 marker	[18]
pHM-SSTR5	hSSTR5 in pGK423	This study




Fig. 2. Fluorescence of a GFP reporter gene in response to agonist stimulation of the endogenous yeast Ste2 receptor in common and feedback activation strains. (A) Fluorescence of GFP reporter genes in the common activation yeast strain (MC-F1) and in the feedback signal activation strain (MC-F1B) with or without 5 μ M α -factor stimulation. (B) Concentration–response curves of MC-F1 and MC-F1B to α -factor. The fluorescence intensities indicate the average values of 10,000 cells. The results are presented as means \pm standard deviations of three independent experiments. w/o, without.

selected on SD solid medium without leucine but containing 20 mg/L uracil and histidine and 30 mg/L methionine (SD-Leu plate) to yield the MC-F1B strain (Table 1).

DNA fragments containing *URA3-P_{FIG1}-STE4-T_{PGK1}-P_{HOP2}* were constructed by overlap extension polymerase chain reaction (PCR) [20]. The *URA3*-containing fragment was amplified from pGK426 [18] using the primers 5'-cagacagcaaatgac ttgatatacgcagctcaattcatcattttttt-3' (corresponding to 30 nt of the region directly upstream of *P_{HOP2}*) and 5'-gcgtttggtgatcattcaagg taataactgatataa ttaattgaagc-3'. The fragment containing *P_{FIG1}-STE4-T_{PGK1}-P_{HOP2}* was amplified from pLMFIG-STE4-H using the primers 5'-gcttcaatttaattatcagttattacccttgaatgatcaaccaacgccgatagtc-3' and 5'-atctttcaaatagagcctgg-3'. These two DNA fragments were ligated and used to transform IMFD-70 [11]. The transformants were selected on SD solid medium without uracil but containing 20 mg/L histidine and 30 mg/L leucine and methionine (SD-Ura plate) to yield the IMFD-70B strain (Table 1). The GPCR expression plasmids pGK411-Ste2 [21] and pHM-SSTR5 were used to transform both IMFD-70 and IMFD-70B strains.

Transcription assay using GFP fluorescent reporter gene

The Fig1p-EGFP (enhanced green fluorescent protein) fusion protein was used as a fluorescent reporter. The yeast cells were incubated at 30 °C, and their fluorescence intensities were then measured using a FACScalibur equipped with a 488-nm air-cooled argon laser (Becton Dickinson). The data were analyzed using CELLQuest software (Becton Dickinson), and the average fluorescence intensity of 10,000 cells was defined as the geometric mean.

Fluorescence microscopic imaging

After incubation for 18 h at 30 °C, the yeast cells were washed and suspended in distilled water. The cell suspensions were observed using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan). Fluorescence images were acquired with a 510-nm band-pass filter for emission.

Results and discussion

General strategy

The aim of this study was to establish a sensitive and robust method for the detection of yeast G-protein signaling in order to enhance the usefulness of yeast-based systems for screening of agonistic ligands of human GPCRs. Our strategy was designed to trigger feedback activation of G-protein signaling through signal-induced expression of an artificial signal activator. The endogenous yeast G β subunit was selected as the signal activator because overexpression of G β constitutively activates the MAPK cascade through effector proteins even in the absence of agonists [22–24]. As shown in Fig. 1B, overexpression of a signal-responsive G β subunit is expected to result in the generation of free G $\beta\gamma$ complexes by competing with the endogenous γ -associated β subunit for binding to the α subunit. This competition would result in the release of free $\beta\gamma$ dimers, which could then amplify the weak signal caused by partial coupling between the heterologous human GPCR and the endogenous yeast G-protein.

Based on the above theory, we constructed a recombinant yeast strain in which overexpression of the *STE4* gene that encodes the

yeast G β subunit can be induced by the signal-responsive *FIG1* promoter [11–15]. Initiation of G-protein signaling in this yeast by agonist stimulation was expected to lead to a feedback activation of G-protein signaling through this overexpressed G β subunit (Fig. 1B). We termed this strategy *feedback signal activation*. The endogenous yeast GPCR, the Ste2 receptor that interacts with endogenous yeast G-proteins, was first used to test our hypothesis that overexpression of a signal-responsive G β subunit would invoke feedback signal activation. Subsequently, the hSSTR5 was used to verify that such feedback signal activation allows highly sensitive and robust detection of agonists of human GPCRs on yeast cell surfaces.

Demonstration of feedback signal activation using the endogenous yeast GPCR

To validate our hypothesis, we constructed the yeast strain, MC-F1B, in which overexpression of the *STE4* gene is under the control of the signal-responsive *FIG1* promoter (Table 1). MC-F1B is derived from the MC-F1 yeast strain in which the chromosomal gene that encodes the endogenous yeast Ste2 receptor is intact and in which a *GFP* reporter gene is integrated at the *FIG1* locus to detect signaling in response to agonist stimulation (Table 1) [17].

The fluorescence of the *GFP* reporter gene in these two yeast strains was quantitatively evaluated during cultivation with 5 μ M α -factor (an Ste2p agonist) in YPD medium. As shown in Fig. 2A, the modified strain (MC-F1B) displayed almost the same fluorescence intensity as the parental strain (MC-F1) over the first 6 h of cultivation. Subsequently, although the fluorescence of MC-F1 dramatically decreased due to inactivation of Ste2p signaling following receptor desensitization, the fluorescence of the MC-

F1B strain was prolonged and GFP fluorescence was augmented for up to 12 h of cultivation. This result indicated that induction of the integrated *STE4* gene amplified signaling induced by Ste2p and that the overexpressed G β protein successfully invoked feedback activation of yeast G-protein signaling.

We further investigated the α -factor concentration dependency of this signaling to determine the ligand sensitivity of these strains. Data obtained after 12 h of cultivation were used to construct concentration–response curves (Fig. 2B). In the case of MC-F1, fluorescence intensity started to strongly increase at a concentration of approximately 5 μ M α -factor and reached a maximum level at a concentration of 10–50 μ M α -factor in a manner similar to that reported previously [25]. The half-maximal effective concentration (EC_{50}) value was 7 μ M. In contrast, the fluorescence intensity of MC-F1B began to increase at a concentration of approximately 500 nM α -factor and reached its maximum at a concentration of 5 μ M α -factor. The EC_{50} value was 800 nM. A similar difference in dose responses was also confirmed even when comparing the MC-F1 and MC-F1B at each optimal cultivation time (MC-F1 at 6 h and MC-F1B at 12 h) (see Supplementary Fig. S1 in supplementary material).

Although these results demonstrated that our feedback signal activation strategy is viable and can expand the detection limit of GPCR signaling to a lower concentration of agonistic ligand α -factor, the maximum intensity of GFP fluorescence at higher concentrations of α -factor did not increase (Fig. 2B). These data likely reflect the fact that the endogenous Ste2 receptor can couple efficiently with its intracellular cognate yeast G-protein in response to a native agonist, the α -factor.

Expression of the yeast Ste2 receptor using an episomal plasmid in a gene-deleted strain

Most heterologous GPCR assays in yeast systems are performed in several types of gene deletion mutants. Thus, the *SST2*-deleted strain confers hypersensitivity toward agonistic ligands, and the *FAR1*-deficient strain allows cell growth and plasmid recovery even in signal-activated states [21]. Moreover, the endogenous yeast *STE2* gene is often deleted to avoid competition of Ste2 receptor expression on the cell surface with that of human GPCRs [21]. Target GPCRs are commonly expressed from episomal plasmids in such yeast strains.

Unfortunately, however, signaling levels observed using episomal plasmid expression systems are frequently lower than those observed using chromosomal expression systems. One possible explanation of this difference might be due to the different cultivation conditions with YPD and SD media. To examine whether feedback signal activation can occur when using GPCRs expressed from episomal plasmids in strains with Ste2 and other deletions, we selected the IMFD-70 strain, which has triple deletion alleles (*sst2* Δ , *far1* Δ , and *ste2* Δ) and *GFP* reporter genes, as the parental yeast strain (Table 1) [11]. We then integrated the artificial signal activator *STE4* gene into the IMFD-70 chromosome, yielding the IMFD-70B strain (Table 1). To model episomal expression systems, the single-copy autonomous replicating plasmid for expression of the endogenous yeast Ste2 receptor (pGK411-STE2) [21] was introduced into both IMFD-70 and IMFD-70B strains.

The fluorescence of the *GFP* reporter gene of these two strains was then quantitatively evaluated during cultivation with 50 nM α -factor in SD selection medium. As shown in Fig. 3A, IMFD-70B/Ste2p (the feedback activation strain) maintained GFP fluorescence for a longer time (up to 18 h) than IMFD-70/Ste2p (the common activation strain, up to 12 h). This increased time of GFP fluorescence in the *STE4* gene-overexpressing strain is similar to the results of strains with chromosomal *STE2* genes. However, unlike strains that express chromosomal Ste2p, IMFD-70B/Ste2p dis-




Fig. 3. Fluorescence of a *GFP* reporter gene in response to agonist stimulation of common and feedback activation strains of yeast expressing the endogenous yeast Ste2 receptor gene from an episomal plasmid. (A) Fluorescence of the *GFP* reporter gene in the common activation strain (IMFD-70/Ste2p) and in the feedback signal activation strain (IMFD-70B/Ste2p) with or without 50 nM α -factor stimulation. (B) Concentration–response curves of IMFD-70/Ste2p and IMFD-70B/Ste2p to α -factor. The fluorescence intensities are the average values of 10,000 cells. The results are presented as means \pm standard deviations of three independent experiments. w/o, without.

played significantly higher fluorescence intensity than IMFD-70/Ste2p even before inactivation of signaling in IMFD-70/Ste2p (before 12 h). These results indicate that feedback signal activation was successfully invoked even when using an episomal plasmid expression system.

Concentration–response curves of these cells were constructed at 18 h of cultivation (Fig. 3B). Whereas the fluorescence intensity of IMFD-70/Ste2p started to increase from a concentration of approximately 50 nM α -factor and reached a maximum level at 500 nM α -factor, that of IMFD-70B/Ste2p gradually increased between concentrations of 500 pM and 500 nM α -factor. The EC_{50} values were 180 nM (IMFD-70/Ste2p) and 20 nM (IMFD-70B/Ste2p), respectively. A similar tendency in the difference of the dose responses was observed when comparing these strains at each optimal cultivation time (IMFD-70/Ste2p at 12 h and IMFD-70B/Ste2p at 18 h) (see Supplementary Fig. S2A). Increases in GFP fluorescence of the intensity observed in IMFD-70B/Ste2p have never been observed in non-feedback activation systems even at much higher concentrations of α -factor (data not shown). The concentration ranges of agonistic ligand required for signal activation in the episomal plasmid system were much lower than those required in the chromosomal system because of the hypersensitivity caused by the *SST2* deletion. In addition, both the detection limit and the maximum intensity of GFP fluorescence were apparently improved by feedback signal activation in the episomal system.

Feedback signal activation significantly improves the sensitivity of agonist detection, and the response to agonist stimulation, of the hSSTR5 receptor

Somatostatin (SST) is a cyclic neuropeptide known as a growth hormone release-inhibiting factor, and its receptors are

therapeutic targets of acromegaly, Cushing's disease, and Alzheimer's disease [26–28]. To investigate whether feedback signal activation successfully rescues the partial activation of human GPCRs (which varies in strength depending on the coupling efficiency of the GPCR with yeast G-proteins) in yeast cells, we assayed SST stimulation of its GPCR, hSSTR5 [11].

An hSSTR5 expression plasmid (pHM-SSTR5) was introduced into IMFD-70 and IMFD-70B strains (Table 1). Each transformant was cultivated in SDM71 medium for signaling assay. Concentration–response curves of these cells were constructed by quantitative evaluation of the GFP fluorescence of both strains after 18 h of cultivation in the presence of several concentrations of SST (Fig. 4A). IMFD-70/hSSTR5 (the common activation strain) displayed a gradual increase in fluorescence intensity at concentrations of SST between 10 nM and 1 μ M, and these responses were remarkably similar to those of a previous study [11]. However, the GFP fluorescence intensity of IMFD-70B/hSSTR5 (the feedback activation strain) was higher than that of the common activation strain at all SST concentrations tested. A similar result was obtained from the data at each optimal cultivation time (IMFD-70/hSSTR5 at 12 h and IMFD-70B/hSSTR5 at 18 h) (see Supplementary Fig. S2B). Moreover, compared with the GFP fluorescence induced by Ste2p in the IMFD-70 strain (the common activation strain), the level of hSSTR5 signaling was obviously lower, whereas the GFP fluorescence intensity of the Ste2p and hSSTR5 IMFD-70B strains (feedback activation strain) was equivalent (Fig. 4A). The EC_{50} value of the IMFD-70B/hSSTR5 strain was clearly improved as compared with that of the IMFD-70/hSSTR5 strain (from 55 to 8 nM). In addition, the advantage of IMFD-70B/hSSTR5 was supported by the fact that the EC_{50} value of the IMFD-70/hSSTR5 strain was almost similar to the value reported previously (109 nM) [11]. These results suggest that feedback signal activation compensates




Fig. 4. Fluorescence of a GFP reporter gene in response to agonist stimulation of common and feedback activation strains of yeast expressing hSSTR5. (A) Concentration–response curves of the common activation strain (IMFD-70/hSSTR5) and the feedback signal activation strain (IMFD-70B/hSSTR5) to the agonistic ligand SST. The dashed lines are overlays of the concentration–response curves of IMFD-70/Ste2p and IMFD-70B/Ste2p (data of Fig. 3B), which are included for comparative purposes. (B) Fluorescence of the GFP fluorescence reporter gene in IMFD-70/hSSTR5 and IMFD-70B/hSSTR5 with or without 1 μ M SST stimulation. The fluorescence intensities are the average values of 10,000 cells. The results are presented as means \pm standard deviations of three independent experiments. (C) Visualization of the green fluorescence of IMFD-70B/hSSTR5 with or without 100 nM SST. The upper photographs are differential interference contrast micrographs, and the lower photographs are fluorescence micrographs. w/o, without.

for inefficient receptor–G-protein coupling efficiency and significantly improves the sensitivity of agonist detection and the response to hSSTR5.

SST (1 μ M) induced 5.8- and 10.8-fold increases over the signaling levels of unstimulated cells without agonistic ligands in the common and feedback activation strains, respectively (Fig. 4B). In addition, using a fluorescence microscope, we visually observed the changes in GFP fluorescence and morphology [29] in response to the SST-induced signal in the feedback activation strain (Fig. 4C). These results suggest that GFP fluorescence was specifically induced by agonists in the feedback activation strain and demonstrate the superiority and reliability of this approach for the detection of human GPCR agonists.

Conclusion

By expression of an artificial signal activator (G β) of the yeast G-protein signaling pathway, we have established a powerful approach for the detection of agonistic ligands of human GPCRs that are regarded as pharmaceutical and therapeutic targets. Using hSSTR5 as a model receptor, we demonstrated that feedback signal activation expands the detection limit for GPCR ligands and the maximum level of GPCR signaling in yeast. Our method is a reliable and versatile tool that could enhance the usefulness of yeast-based screening of agonistic ligands for a variety of human GPCRs.

Acknowledgments

This work was supported by a Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science and, in part, by Special Coordination Funds for Promoting Science and Technology, Creation of Innovation Centers for Advanced Interdisciplinary Research Areas (Innovative Bioproduction Kobe), Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ab.2011.06.006.

References

- [1] A.L. Hopkins, C.R. Groom, The druggable genome, *Nat. Rev. Drug Discov.* 1 (2002) 727–730.
- [2] J. Giacomotto, L. Ségalat, High-throughput screening and small animal models: where are we?, *Br. J. Pharmacol.* 160 (2006) 204–216.
- [3] G.D. Stewart, C. Valant, S.J. Dowell, D. Mijaljica, R.J. Devenish, P.J. Scammells, P.M. Sexton, A. Christopoulos, Determination of adenosine A1 receptor agonist and antagonist pharmacology using *Saccharomyces cerevisiae*: implications for ligand screening and functional selectivity, *J. Pharmacol. Exp. Ther.* 331 (2009) 277–286.
- [4] J. Minic, M. Sautel, R. Salesses, E. Pajot-Augy, Yeast system as a screening tool for pharmacological assessment of G-protein coupled receptors, *Curr. Med. Chem.* 12 (2005) 961–969.
- [5] J.P. Manfredi, C. Klein, J.J. Herrero, D.R. Byrd, J. Trueheart, W.T. Wiesler, D.M. Fowlkes, J.R. Broach, Yeast α mating factor structure-activity relationship derived from genetically selected peptide agonists and antagonists of Ste2p, *Mol. Cell. Biol.* 16 (1996) 4700–4709.
- [6] M.H. Pausch, M. Lai, E. Tseng, J. Paulsen, B. Bates, S. Kwak, Functional expression of human and mouse P2Y12 receptors in *Saccharomyces cerevisiae*, *Biochem. Biophys. Res. Commun.* 324 (2004) 171–177.
- [7] E.V. Shusta, P.D. Holler, M.C. Kieke, D.M. Kranz, K.D. Wittrup, Directed evolution of a stable scaffold for T-cell receptor engineering, *Nat. Biotechnol.* 18 (2000) 754–759.
- [8] M.J. Feldhaus, R.W. Siegel, L.K. Opreko, J.R. Coleman, J.M. Feldhaus, Y.A. Yeung, J.R. Cochran, P. Heinzelman, D. Colby, J. Swers, C. Graff, H.S. Wiley, K.D. Wittrup, Flow-cytometric isolation of human antibodies from a nonimmune *Saccharomyces cerevisiae* surface display library, *Nat. Biotechnol.* 21 (2003) 163–170.
- [9] N. Fukuda, J. Ishii, S. Shibasaki, M. Ueda, H. Fukuda, A. Kondo, High-efficiency recovery of target cells using improved yeast display system for detection of protein–protein interactions, *Appl. Microbiol. Biotechnol.* 76 (2007) 151–158.
- [10] G. Ladds, A. Goddard, J. Davey, Functional analysis of heterologous GPCR signalling pathways in yeast, *Trends Biotechnol.* 23 (2005) 367–373.
- [11] S. Togawa, J. Ishii, A. Ishikura, T. Tanaka, C. Ogino, A. Kondo, Importance of asparagine residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signalling, *J. Biochem.* 147 (2010) 867–873.
- [12] N. Fukuda, J. Ishii, T. Tanaka, H. Fukuda, A. Kondo, Construction of a novel detection system for protein–protein interactions using yeast G-protein signaling, *FEBS J.* 276 (2009) 2636–2644.
- [13] N. Fukuda, J. Ishii, T. Tanaka, A. Kondo, The competitor-introduced Gy recruitment system, a new approach for screening affinity-enhanced proteins, *FEBS J.* 277 (2010) 1704–1712.
- [14] J. Ishii, N. Fukuda, T. Tanaka, C. Ogino, A. Kondo, Protein–protein interactions and selection: yeast-based approaches that exploit guanine nucleotide-binding protein signaling, *FEBS J.* 277 (2010) 1982–1995.
- [15] Y. Iguchi, J. Ishii, H. Nakayama, A. Ishikura, K. Izawa, T. Tanaka, C. Ogino, A. Kondo, Control of signalling properties of human somatostatin receptor subtype-5 by additional signal sequences on its amino-terminus in yeast, *J. Biochem.* 147 (2010) 875–884.
- [16] C.B. Brachmann, A. Davies, G.J. Cost, E. Caputo, J. Li, P. Hieter, J.D. Boeke, Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: A useful set of strains and plasmids for PCR-mediated gene disruption and other applications, *Yeast* 14 (1998) 115–132.
- [17] N. Fukuda, J. Ishii, A. Kondo, Gy recruitment system incorporating a novel signal amplification circuit to screen transient protein–protein interactions, *FEBS J.* (2011), doi:10.1111/j.1742-4658.2011.08232.x.
- [18] J. Ishii, K. Izawa, S. Matsumura, K. Wakamura, T. Tanino, T. Tanaka, C. Ogino, H. Fukuda, A. Kondo, A simple and immediate method for simultaneously evaluating expression level and plasmid maintenance in yeast, *J. Biochem.* 145 (2009) 701–708.
- [19] D. Gietz, A. St. Jean, R.A. Woods, R.H. Schiestl, Improved method for high efficiency transformation of intact yeast cells, *Nucleic Acids Res.* 20 (1992) 1425.
- [20] S.N. Ho, H.D. Hunt, R.M. Horton, J.K. Pullen, L.R. Pease, Site-directed mutagenesis by overlap extension using the polymerase chain reaction, *Gene* 77 (1989) 51–59.
- [21] J. Ishii, T. Tanaka, S. Matsumura, K. Tatematsu, S. Kuroda, C. Ogino, H. Fukuda, A. Kondo, Yeast-based fluorescence reporter assay of G-protein-coupled receptor signalling for flow cytometric screening: *FAR1* -disruption recovers loss of episomal plasmid caused by signalling in yeast, *J. Biochem.* 143 (2008) 667–674.
- [22] S. Nomoto, N. Nakayama, K. Arai, K. Matsumoto, Regulation of the yeast pheromone response pathway by G protein subunits, *EMBO J.* 9 (1990) 691–696.
- [23] M. Whiteway, L. Hougan, D.Y. Thomas, Overexpression of the STE4 gene leads to mating response in haploid *Saccharomyces cerevisiae*, *Mol. Cell. Biol.* 10 (1990) 217–222.
- [24] K.L. Clark, D. Dignard, D.Y. Thomas, M. Whiteway, Interactions among the subunits of the G protein involved in *Saccharomyces cerevisiae* mating, *Mol. Cell. Biol.* 13 (1993) 1–8.
- [25] J. Ishii, S. Matsumura, S. Kimura, K. Tatematsu, S. Kuroda, H. Fukuda, A. Kondo, Quantitative and dynamic analyses of G-protein-coupled receptor signaling in yeast using Fus1, enhanced green fluorescence protein (EGFP), and His3 fusion protein, *Biotechnol. Prog.* 22 (2006) 954–960.
- [26] T. Saito, N. Iwata, S. Tsubuki, Y. Takaki, J. Takano, S.M. Huang, T. Suemoto, M. Higuchi, T.C. Saïdo, Somatostatin regulates brain amyloid β peptide A β 42 through modulation of proteolytic degradation, *Nat. Med.* 11 (2005) 434–439.
- [27] S.W. Lamberts, W.W. de Herder, E.P. Krenning, J.C. Reubi, A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome, *J. Clin. Endocrinol. Metab.* 78 (1994) 17–19.
- [28] A. Ben-Shlomo, S. Melmed, Somatostatin agonists for treatment of acromegaly, *Mol. Cell. Endocrinol.* 286 (2008) 192–198.
- [29] L. Yu, M. Qi, M.A. Sheff, E.A. Elion, Counteractive control of polarized morphogenesis during mating by mitogen-activated protein kinase Fus3 and G1 cyclin-dependent kinase, *Mol. Biol. Cell* 19 (2008) 1739–1752.

Cell Wall Trapping of Autocrine Peptides for Human G-Protein-Coupled Receptors on the Yeast Cell Surface

Jun Ishii¹, Nobuo Yoshimoto^{2,3}, Kenji Tatematsu², Shun'ichi Kuroda^{2,3}, Chiaki Ogino⁴, Hideki Fukuda⁴, Akihiko Kondo^{4*}

1 Organization of Advanced Science and Technology, Kobe University, 1-1 Rokkodai, Nada, Kobe, Japan, **2** Department of Structural Molecular Biology, Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka, Japan, **3** Graduate School of Bioagricultural Sciences, Nagoya University, Furo, Chikusa, Nagoya, Japan, **4** Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe, Japan

Abstract

G-protein-coupled receptors (GPCRs) regulate a wide variety of physiological processes and are important pharmaceutical targets for drug discovery. Here, we describe a unique concept based on yeast cell-surface display technology to selectively track eligible peptides with agonistic activity for human GPCRs (Cell Wall Trapping of Autocrine Peptides (CWTrAP) strategy). In our strategy, individual recombinant yeast cells are able to report autocrine-positive activity for human GPCRs by expressing a candidate peptide fused to an anchoring motif. Following expression and activation, yeast cells trap autocrine peptides onto their cell walls. Because captured peptides are incapable of diffusion, they have no impact on surrounding yeast cells that express the target human GPCR and non-signaling peptides. Therefore, individual yeast cells can assemble the autonomous signaling complex and allow single-cell screening of a yeast population. Our strategy may be applied to identify eligible peptides with agonistic activity for target human GPCRs.

Citation: Ishii J, Yoshimoto N, Tatematsu K, Kuroda S, Ogino C, et al. (2012) Cell Wall Trapping of Autocrine Peptides for Human G-Protein-Coupled Receptors on the Yeast Cell Surface. PLoS ONE 7(5): e37136. doi:10.1371/journal.pone.0037136

Editor: Debra Kendall, University of Connecticut, United States of America

Received: December 16, 2011; **Accepted:** April 13, 2012; **Published:** May 18, 2012

Copyright: © 2012 Ishii et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas (Life surveyor) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Regional Innovative Consortium Project of the Ministry of Economy, Trade and Industry (METI) and a Special Coordination Funds for Promoting Science and Technology, Creation of Innovation Centers for Advanced Interdisciplinary Research Areas (Innovative Bioproduction Kobe; iBioK) from the MEXT of Japan, and funded in part by AS ONE Corporation and the Naito Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: This work was supported in part by AS ONE Corporation. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: akondo@kobe-u.ac.jp

Introduction

G-protein-coupled receptors (GPCRs) constitute a large super-family of cell surface receptors [1]. In humans, these 7-transmembrane proteins respond to external stimuli to regulate various cellular processes including taste, smell, vision, heart rate, blood pressure, neurotransmission and cell growth [2]. All members of the guanine nucleotide binding protein family (G-proteins) share a common mechanism for signal transmission following GPCR-agonist binding [3]. This universal signaling mechanism has become a central tenet in G-protein research, and GPCRs have become major pharmaceutical targets for drug discovery [4].

The eukaryotic unicellular yeast, *Saccharomyces cerevisiae*, also shares the G-protein-mediated signal transmission mechanism with higher mammalian cells [3]. It is notable that *S. cerevisiae* offers a crucial advantage to simplify the study of GPCR signaling because it expresses only one kind of G-protein, which thereby avoids potential problems such as signaling cross-talk in mammalian cells [5–8]. Therefore, *S. cerevisiae* is a suitable host cell for the screening of functional residues in GPCRs [5,9,10].

Yeast cell-surface display technology is a powerful platform that enables proteins expressed in yeast to be tethered onto the cell surface [11–15]. This is accomplished by the use of “anchor” proteins that naturally localize on the cell surface in yeast cells. Typically, the gene encoding the target protein is fused to the

anchor protein together with a secretion signal sequence at the N-terminus to both enable secretion of the fusion protein and to tether it firmly to the cell surface. As typical anchor proteins, the C-terminal domains of truncated α -agglutinin (Sag1p; a manno-protein involved in sexual adhesion) and truncated Flo1p (a lectin-like cell-wall protein involved in flocculation) containing the glycosyl-phosphatidylinositol (GPI) anchor attachment signal sequence at the C-terminus are fused to the target protein at their N-termini [16,17]. Regarding other anchor proteins, the Flo1p flocculation functional domain without the GPI anchor attachment signal (FS anchor) permits the fusion of the target protein to both its N- and C-termini [18]. These anchor proteins are used to display the target proteins on the yeast cell wall. In contrast, periplasmic invertase (Suc2 anchor) can be fused to both the N- and C-termini of a target protein, enabling it to localize into the periplasmic space [19]. To date, yeast cell-surface display technology has been adopted for a broad range of applications including enzymatic catalysis, immune adsorption and protein engineering [16–18,20–23].

Here, we describe a unique concept using yeast cell-surface display technology to selectively track eligible peptides that present agonistic activity for human GPCRs. In our system, individual yeast cells expressing human GPCRs fulfill a series of roles from the manufacture of peptides to the sensing of agonistic activity. Briefly, yeast cells synthesize candidate peptides in fusion with

a secretion signal sequence and an anchoring motif. Agonistic peptides are capable of binding cell surface GPCRs that transduce the signal into the cell. Finally, the yeast traps the signaling peptide on its cell wall (Figure 1). Here, we use a yeast strain that is engineered to express a green fluorescent protein (*GFP*) reporter gene in response to GPCR activation. Therefore, stimulation by agonistic peptides can be recognized by the generation of a green fluorescence signal [3]. In principle, because signaling peptides are unable to diffuse to surrounding cells, our strategy has the potential to build autonomous signaling complexes on a cell-by-cell basis. Our peptide trapping method (cell wall trapping of autocrine peptides (CWTrAP) system) will allow the identification of lead peptides from combinatorial peptide libraries as starting points for drug screening.

Results and Discussion

To corroborate the viability of cell-surface display technology to track agonistic activity for GPCRs (CWTrAP system), we used α -factor pheromone, a natural ligand for the endogenous yeast 7-transmembrane GPCR, Ste2, which is specifically expressed in the *a*-type-strain [24]. In nature, α -type yeast strains secrete α -factor to induce mating signal transduction in the *a*-type strain by binding to the Ste2 receptor on its cell surface [25]. The ability of several types of protein motifs to anchor and transduce the autocrine α -factor were tested in the recombinant *a*-type yeast cells, which can express a *GFP* reporter gene in response to pheromone signaling (Figure 1). All constructs of fusion proteins that displayed α -factor peptides were designed to contain a Flag tag between the α -factor peptides and anchor proteins (Figure 2A and Table 1).

We used the IMG-4 yeast strain to display α -factor pheromone on its cell surface because this strain can monitor signaling levels through its endogenous Ste2 receptor via a *GFP* reporter gene

(Table 1). To test our concept, we evaluated the C-terminal 320 aa of Sag1p (C-terminal half of α -agglutinin; AG) [16] and various lengths of truncated Flo1p derivatives (C-terminal 42, 102, 146 and 318 aa of Flo1p; Flo42, Flo102, Flo146 and Flo318) [17] as anchor proteins with GPI anchoring motifs (Figure 2A and Table 1). A recombinant yeast strain, engineered to express the α -factor autocrine peptide with a secretion signal sequence but lacking an anchor motif, robustly generated a higher green fluorescence signal than a strain harboring a mock plasmid (Figure 3A, Mock and Sec). Immunofluorescence staining of Flag-tagged α -factor peptide revealed no fluorescence on the surface of engineered yeast cells (Figure 3B, Sec). These results suggest that secreted α -factor could bind the endogenous Ste2 receptor and transduce the signal inside the yeast cells.

Next, we tested the cell wall trapping (CWTrAP) strategy for α -factor peptide with GPI anchoring motifs. All engineered yeast strains expressing α -factor peptides fused to the N-termini of the anchor proteins (AG and Flo42 318) with an inserted Flag tag (Figure 2A) successfully generated a green fluorescence signal (Figure 3A), confirming that the fusion peptide is able to activate signal transduction in yeast. Using GFP fluorescence intensity as an indicator of signaling strength, shorter anchor peptides appeared more capable of activating the GPCR (Figure 3A). The α -factor peptide fused to Flag and Flo42 exhibited higher responsiveness compared to α -factor lacking the anchor protein. This interesting result may arise from the transient enrichment of the GPI-anchored peptide on the yeast cell membrane, although the GPI-anchored peptide should be cleaved from the plasma membrane by phosphatidylinositol-specific phospholipase C (PI-PLC) and tethered on the cell wall [11–13].

Although shorter peptides tend to make detection of the Flag tag more difficult, due to the report that shorter peptides can bury the tag within the cell wall [17], we were able to confirm an anchor-dependent association with the yeast cell wall by immunofluores-




Figure 1. Schematic illustration of our concept using yeast cell-surface display technology to selectively track eligible agonistic peptides for human GPCRs by assembling the autonomous signaling complex within individual cells (cell wall trapping of autocrine peptides (CWTrAP) strategy). The candidate autocrine peptides fused with the anchoring proteins are processed via secretion pathways in engineered yeast cells. Their agonistic activities for heterologously-expressed human GPCRs are discerned on yeast cell membranes. Only when the peptide possesses objective agonistic activity, membrane-peripheral G-proteins promote intracellular signaling and induce transcription of the *GFP* reporter gene. Because the autocrine peptides are automatically trapped onto individual yeast cell walls, the captured peptides are unable to diffuse toward surrounding yeast cells that express the target human GPCR and any other peptides. T.F. indicates transcription factor. doi:10.1371/journal.pone.0037136.g001




Figure 2. Schematic illustration of the fusion protein constructs used to display agonistic peptides on the yeast cell-surface. (A) Constructs for displaying α -factor peptides. AG: C-terminal half of α -agglutinin anchor. s.s.: secretion signal sequence. The pre-pro-region derived from α -factor was used as s.s. For the fusion of FS and Suc2 anchors to the α -factor peptides at their C-termini, the original s.s. encoded in the N-termini of Flo1p or Suc2p were used, respectively. The uppermost construct for secretion of α -factor peptide contains no anchoring motifs. All constructs contain the Flag tag. (B) Constructs for displaying S-14 by the Flo42 anchor. The upper construct displaying only Flag and Flo42 peptides was used as a negative control for the SSTR5 signaling assay. The middle and lower constructs displaying, respectively, eligible peptide (S-14) and negative control peptides (α -factor, All and ET1) by Flag-Flo42 fusion proteins were also used for the SSTR5 signaling assay. doi:10.1371/journal.pone.0037136.g002

cence staining (Figure 3B). Because peptides anchored to the cell wall are unable to diffuse to surrounding cells, this result emphasizes the viability of our concept for the assembly of the autonomous signaling complex within individual yeast cells. Additionally, we verified that a subset of Flo42 was highly glycosylated (Figure S1); however, the agonistic activity of the α -factor peptide was unlikely to be affected by the posttranslational glycosylation of the anchor protein.

Next, we tested additional motifs that permit peptides to be fused to both the N- and C-termini of the anchor proteins. We replaced the GPI anchor proteins with the FS anchor [18] and the Suc2 anchor [19] (Figure 2A, Table S2 and Document S1). Signal transduction was more efficient when using the FS anchor, compared to the Suc2 anchor (Figure S2). These results show that agonistic peptides can be fused to both the N- and C-termini of anchor proteins. Even though the FS anchor (1099 aa) served as an efficient motif for transducing α -factor peptide signaling, we used the Flo42 anchor motif, whose molecular mass is much lower (Figure 2A), in all following experiments in order to minimize the possibility of steric hindrance.

To further demonstrate the viability of our concept, the IMFD-70 yeast strain, which can monitor signaling levels from recombinantly expressed heterologous GPCRs by a *GFP* reporter

gene [5] (Table 1), was used to test if signal transmission from human GPCRs expressed on the yeast cell surface was possible. For these experiments, human somatostatin receptor subtype 5 (SSTR5), and the natural intramolecular-cross-linked cyclic peptide ligand, somatostatin 14 (S-14), were used [26,27].

To express the autocrine somatostatin and trap it on the yeast cell wall, we designed the S-14 peptide with an N-terminal secretion signal sequence and a C-terminal Flo42 anchor protein with a Flag tag (Figure 2B and Table 1). We constructed several negative controls by eliminating the S-14 peptide or by replacing it with agonistic peptides for other GPCRs (Figure 2B and Table 1). We expressed hemagglutinin (HA)-tagged human SSTR5 on the yeast cell surface using previously reported plasmids [5,6] (Table 1). We used these expression and mock plasmids to investigate the ability of the S-14 Flag-Flo42 autocrine peptide to activate GPCR signaling (Figure 4).

As shown in Figure 4A, the engineered yeast strain concomitantly expressing SSTR5 HA and S-14 Flag-Flo42 successfully induced *GFP* reporter gene expression, whereas the other control strains possessing either SSTR5 HA or S-14 Flag Flo42 did not. Similarly, a control strain expressing SSTR5-HA and the autocrine Flag Flo42 fusion protein lacking the S-14 peptide was unable to express a green fluorescence signal (Figure 4A).

Table 1. Yeast strains and plasmids used in this study.

Strain or plasmid	Relative feature	Source
Yeast strain		
BY4741	<i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</i>	[31]
IMG-4	BY4741 <i>fus1::FUS1-EGFP-T_{GAPDH}-HIS3 bar1Δ::LEU2 far1Δ::kanMX4</i>	This study
IMG-50	BY4741 <i>fus1::FUS1-EGFP-T_{GAPDH}-HIS3 sst2Δ::AUR1-C ste2Δ::LEU2</i>	[28]
IMFD-70	BY4741 <i>flg1Δ::EGFP his3Δ::P_{FIG1}-EGFP far1Δ sst2Δ::AUR1-C ste2Δ::LEU2</i>	[5]
Plasmid		
pESC-URA ^a	Expression vector containing <i>GAL1-GAL10</i> divergent promoter, 2μ origin and <i>URA3</i> marker	Agilent Technologies
pUESCαsf	pESC-URA, α-factor-Flag peptide expression (for secretion)	This study
pUESCαf-AG	pESC-URA, α-factor-Flag-AG ^b fusion protein expression (for display)	This study
pUESCαf-FLO42	pESC-URA, α-factor-Flag-Flo42 fusion protein expression (for display)	This study
pUESCαf-FLO102	pESC-URA, α-factor-Flag-Flo102 fusion protein expression (for display)	This study
pUESCαf-FLO146	pESC-URA, α-factor-Flag-Flo146 fusion protein expression (for display)	This study
pUESCαf-FLO318	pESC-URA, α-factor-Flag-Flo318 fusion protein expression (for display)	This study
pGK421 ^a	Expression vector containing <i>PGK1</i> promoter, 2μ origin and <i>MET15</i> marker	[5,6]
pGK-SSTR5-HA	pGK421, SSTR5-HA human receptor expression	[5,6]
pGK426 ^a	Expression vector containing <i>PGK1</i> promoter, 2μ origin and <i>URA3</i> marker	[36]
pGK42	pGK426, Flag-Flo42 anchor protein expression (for display)	This study
pGK-S1442	pGK426, S-14-Flag-Flo42 ^c fusion protein expression (for display)	This study
pGK-alpha42	pGK426, α-factor-Flag-Flo42 fusion protein expression (for display)	This study
pGK-AII42	pGK426, AII-Flag-Flo42 ^d fusion protein expression (for display)	This study
pGK-ET142	pGK426, ET1-Flag-Flo42 ^e fusion protein expression (for display)	This study
pMHG-FIG1	Multi-copy reporter plasmid containing <i>FIG1</i> promoter, <i>GFP</i> reporter gene, 2μ origin and <i>HIS3</i> marker	[6]

All transcription products for display or secretion contain the secretion signal sequence of α-factor.

^aThe indicated vectors were used as mock controls.

^bAG indicates C-terminal half of α-agglutinin anchor protein.

^cS-14 encodes somatostatin 14 mature peptide.

^dAll encodes angiotensin II mature peptide.

^eET1 encodes endothelin-1 mature peptide.

doi:10.1371/journal.pone.0037136.t001

These results demonstrate that autocrine activation of recombinant SSTR5 by binding of the S-14 peptide fused to the Flo42 anchor mediates pheromone signaling via endogenous peripheral G-proteins in yeast [5]. Furthermore, we were able to confirm the specificity of the S-14 peptide because three control peptides in which the S-14 peptide was replaced with the yeast Ste2 receptor agonist, α-factor, the human angiotensin receptor agonist, angiotensin II (AII), or the human endothelin receptor agonist, endothelin-1 (ET1), did not generate a green fluorescence signal (Figure 4B).

We confirmed the expression of SSTR5 HA receptor and S-14 Flag Flo42 fusion protein by western blot analysis (Figure 5). Equal loading of the sodium lauryl sulfate (SDS)-extracted cell lysate fraction from each pellet was confirmed using anti-β-actin. SSTR5 HA receptor (anti-HA; lanes 2–4) and Flag-Flo42 anchor or S-14 Flag-Flo42 fusion proteins (anti-Flag; lanes 3–5) were successfully detected in the extracts of each appropriate transformant. The two unequal bands detected by the anti-Flag antibody in the Flag Flo42 and S-14 Flag-Flo42 transformants likely represent the signal-cleaved and -uncleaved proteins, because the pre-pro-region derived from α-factor was used as the secretion signal sequence. We therefore tested the ability of the other active somatostatin isoform S-28 [26] and other secretion signal sequences (pre-region of α-factor and signal sequences derived from *S. cerevisiae* Suc2p and *Rhizopus oryzae* glucoamylase) to mediate signal transduction in the IMG-50 yeast strain. This strain

has a slightly different genetic background to IMFD-70 (*FAR1*-intact strain [28], the description of the *far1Δ* allele can be found in Materials and Methods; Table 1), but the expression profiles of the *GFP* reporter genes remained essentially unchanged (Figure S3). Also, the insertion of GS linkers (GGGGS and GGGSGGGGS) between the S-14 peptide and Flag Flo42 did not improve *GFP* expression (Figure S4). Because GPCR signaling has been reported to decrease plasmid retention even in the *far1Δ* yeast strain [28], false-negative signals (non-signaling cell cluster; Figure 4A, SSTR5 HA/S-14 Flag Flo42) may be caused by plasmid loss. Because other secretion signal sequences and the insertion of GS linkers had no effect on expression of the *GFP* reporter gene, it is unlikely that a false-negative signal would be caused by steric hindrance of the S-14 peptide (Figure S3 and S4). Nevertheless, the presence of false-negative cells within an identical cell cluster implies that peptides captured on the cell wall have little influence on the surrounding cells (Figure 4, S3 and S4). Therefore, we demonstrated that peptides captured on the cell wall did not induce false-positive signals in surrounding non-target cells, even when two types of cells, one expressing the S-14 Flag Flo42 (target cells) and the other expressing the Flag Flo42 anchor lacking S-14 (non-target cells or surrounding cells), were mixed (Figure S5). Additionally, we successfully enhanced the weaker green fluorescence signal of the IMFD-70 strain expressing SSTR5 HA and S-14 Flag-Flo42 (Figure 4A) by concurrently introducing a multi-copy plasmid harboring the *GFP* reporter gene




Figure 3. Evaluation of the CWTrAP system using α -factor peptide for yeast endogenous Ste2 receptor. (A) Pheromone signaling assays of α -factor-displaying yeast strains. Error bars represent the standard deviation of three independent experiments. (B) Immunofluorescence staining of α -factor displaying yeast strains. Anti-Flag antibody and Alexa Fluor 546-conjugated secondary antibody were used for detection of secreted α -factor or α -factor-anchor fusion proteins. IMG-4 was used as the host strain. The transformants used in these experiments are listed in Table S3. Sec: free, secreted form of α -factor. AG: C-terminal half of α -agglutinin anchor. doi:10.1371/journal.pone.0037136.g003

cassette (pMHG-FIG1 [6]) (Figure 6). These results strongly support the feasibility of our conceptual CWTrAP system to identify eligible agonistic peptides for human GPCRs.

Finally, to examine whether the yeast cell wall did indeed trap the autocrine peptide fused to the Flo42 anchor, transformants were analyzed by immunofluorescence staining with anti-Flag primary antibody and Alexa Fluor 594 conjugated secondary antibody (Figure 7). We observed red fluorescence on the cell surfaces of appropriate transformants that expressed Flag Flo42 anchor or S-14-Flag Flo42 fusion proteins. In addition, we only

observed a morphology change [29] on cells expressing both SSTR5 HA and S-14-Flag-Flo42, supporting our hypothesis that the autocrine S-14 peptide specifically triggered signal transduction via the SSTR5 receptor in the recombinant yeast cells. Thus, we successfully verified that the S-14 autocrine peptide fused to the Flo42 anchor protein was trapped on the yeast cell wall.

In this study, we have demonstrated how a strategy for cell wall trapping of autocrine peptides (CWTrAP system) functions to discern agonistic activity for human GPCRs expressed in yeast




Figure 4. Evaluation of the CWTrAP system using somatostatin peptide for the human SSTR5 receptor. (A) SSTR5 signaling assays of the cyclic somatostatin peptide displaying yeast strain and control strains. (B) SSTR5 signaling assays of non-target peptide displaying yeast strains. IMFD-70 was used as the host strain. The transformants used in these experiments are listed in Table S3. S-14 indicates 14 aa of somatostatin cyclic peptide, α -factor indicates 13 aa of yeast pheromone peptide, All indicates 8 aa of angiotensin II peptide, and ET1 indicates 21 aa of endothelin-1 peptide. doi:10.1371/journal.pone.0037136.g004

cells, by using the intramolecular-cross-linked cyclic peptide S-14 and its specific receptor as our model. Our motivation was to selectively track eligible agonistic peptides for human GPCRs by assembling an autonomous signaling complex within individual cells. By combining cell-surface display technology and established yeast combinatorial genetic engineering technology with flow cytometric single-cell screening [30], we aim to identify eligible peptides from peptide libraries. Here, the feasibility of our concept is demonstrated by peptide capture, and subsequent signal transduction, by heterologously-expressed human GPCRs, which prevent the captured peptides from diffusing to surrounding yeast cells and eliciting a false-positive response. Therefore, the captured peptides are successfully presented by yeast cell-surface display technology.

Materials and Methods

Media

Synthetic raffinose (SR) media contained 6.7 g/l yeast nitrogen base without amino acids (YNB) (BD-Diagnostic Systems, Sparks, MD, USA) and 20 g/l raffinose. For SRGC media, 20 g/l galactose and 20 g/l casamino acids (BD-Diagnostic Systems) were added into SR media. Synthetic dextrose (SD) media contained 6.7 g/l YNB and 20 g/l glucose. For SDM71 media, SD media was adjusted to pH 7.1 with 200 mM MOPSO buffer (Nacalai Tesque, Kyoto, Japan). Amino acids and nucleotides (20 mg/l histidine, 60 mg/l leucine, 20 mg/l methionine or 20 mg/l uracil) were supplemented into each medium to provide the relevant auxotrophic components.